Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Identifieur interne : 000251 ( PubMed/Checkpoint ); précédent : 000250; suivant : 000252Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Auteurs : Ashley Barlow [États-Unis] ; Kaitlin M. Landolf [États-Unis] ; Brooke Barlow [États-Unis] ; Siu Yan Amy Yeung [États-Unis] ; Jason J. Heavner [États-Unis] ; Cassidy W. Claassen [Zambie] ; Mojdeh S. Heavner [États-Unis]Source :
- Pharmacotherapy [ 1875-9114 ] ; 2020.
Abstract
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit (ICU) admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacological management of patients with COVID-19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immune modulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS-CoV-2. Critically ill patients with COVID-19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID-19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic.
DOI: 10.1002/phar.2398
PubMed: 32259313
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32259313Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.</title><author><name sortKey="Barlow, Ashley" sort="Barlow, Ashley" uniqKey="Barlow A" first="Ashley" last="Barlow">Ashley Barlow</name><affiliation wicri:level="2"><nlm:affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Landolf, Kaitlin M" sort="Landolf, Kaitlin M" uniqKey="Landolf K" first="Kaitlin M" last="Landolf">Kaitlin M. Landolf</name><affiliation wicri:level="2"><nlm:affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Barlow, Brooke" sort="Barlow, Brooke" uniqKey="Barlow B" first="Brooke" last="Barlow">Brooke Barlow</name><affiliation wicri:level="2"><nlm:affiliation>University of Kentucky Healthcare, Lexington, KY, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Kentucky Healthcare, Lexington, KY</wicri:regionArea><placeName><region type="state">Kentucky</region></placeName></affiliation></author><author><name sortKey="Yeung, Siu Yan Amy" sort="Yeung, Siu Yan Amy" uniqKey="Yeung S" first="Siu Yan Amy" last="Yeung">Siu Yan Amy Yeung</name><affiliation wicri:level="2"><nlm:affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Heavner, Jason J" sort="Heavner, Jason J" uniqKey="Heavner J" first="Jason J" last="Heavner">Jason J. Heavner</name><affiliation wicri:level="2"><nlm:affiliation>University of Maryland Baltimore Washington Medical Center, Glen Burnie, MD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland Baltimore Washington Medical Center, Glen Burnie, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Claassen, Cassidy W" sort="Claassen, Cassidy W" uniqKey="Claassen C" first="Cassidy W" last="Claassen">Cassidy W. Claassen</name><affiliation wicri:level="1"><nlm:affiliation>University of Maryland School of Medicine, Center for International Health, Education, and Biosecurity, Institute of Human Virology, Lusaka, Zambia.</nlm:affiliation><country xml:lang="fr">Zambie</country><wicri:regionArea>University of Maryland School of Medicine, Center for International Health, Education, and Biosecurity, Institute of Human Virology, Lusaka</wicri:regionArea><wicri:noRegion>Lusaka</wicri:noRegion></affiliation></author><author><name sortKey="Heavner, Mojdeh S" sort="Heavner, Mojdeh S" uniqKey="Heavner M" first="Mojdeh S" last="Heavner">Mojdeh S. Heavner</name><affiliation wicri:level="2"><nlm:affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32259313</idno><idno type="pmid">32259313</idno><idno type="doi">10.1002/phar.2398</idno><idno type="wicri:Area/PubMed/Corpus">000315</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000315</idno><idno type="wicri:Area/PubMed/Curation">000315</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000315</idno><idno type="wicri:Area/PubMed/Checkpoint">000251</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000251</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.</title><author><name sortKey="Barlow, Ashley" sort="Barlow, Ashley" uniqKey="Barlow A" first="Ashley" last="Barlow">Ashley Barlow</name><affiliation wicri:level="2"><nlm:affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Landolf, Kaitlin M" sort="Landolf, Kaitlin M" uniqKey="Landolf K" first="Kaitlin M" last="Landolf">Kaitlin M. Landolf</name><affiliation wicri:level="2"><nlm:affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Barlow, Brooke" sort="Barlow, Brooke" uniqKey="Barlow B" first="Brooke" last="Barlow">Brooke Barlow</name><affiliation wicri:level="2"><nlm:affiliation>University of Kentucky Healthcare, Lexington, KY, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Kentucky Healthcare, Lexington, KY</wicri:regionArea><placeName><region type="state">Kentucky</region></placeName></affiliation></author><author><name sortKey="Yeung, Siu Yan Amy" sort="Yeung, Siu Yan Amy" uniqKey="Yeung S" first="Siu Yan Amy" last="Yeung">Siu Yan Amy Yeung</name><affiliation wicri:level="2"><nlm:affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Heavner, Jason J" sort="Heavner, Jason J" uniqKey="Heavner J" first="Jason J" last="Heavner">Jason J. Heavner</name><affiliation wicri:level="2"><nlm:affiliation>University of Maryland Baltimore Washington Medical Center, Glen Burnie, MD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland Baltimore Washington Medical Center, Glen Burnie, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Claassen, Cassidy W" sort="Claassen, Cassidy W" uniqKey="Claassen C" first="Cassidy W" last="Claassen">Cassidy W. Claassen</name><affiliation wicri:level="1"><nlm:affiliation>University of Maryland School of Medicine, Center for International Health, Education, and Biosecurity, Institute of Human Virology, Lusaka, Zambia.</nlm:affiliation><country xml:lang="fr">Zambie</country><wicri:regionArea>University of Maryland School of Medicine, Center for International Health, Education, and Biosecurity, Institute of Human Virology, Lusaka</wicri:regionArea><wicri:noRegion>Lusaka</wicri:noRegion></affiliation></author><author><name sortKey="Heavner, Mojdeh S" sort="Heavner, Mojdeh S" uniqKey="Heavner M" first="Mojdeh S" last="Heavner">Mojdeh S. Heavner</name><affiliation wicri:level="2"><nlm:affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j">Pharmacotherapy</title><idno type="eISSN">1875-9114</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit (ICU) admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacological management of patients with COVID-19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immune modulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS-CoV-2. Critically ill patients with COVID-19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID-19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32259313</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-9114</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>Pharmacotherapy</Title><ISOAbbreviation>Pharmacotherapy</ISOAbbreviation></Journal><ArticleTitle>Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/phar.2398</ELocationID><Abstract><AbstractText>The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit (ICU) admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacological management of patients with COVID-19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immune modulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS-CoV-2. Critically ill patients with COVID-19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID-19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barlow</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landolf</LastName><ForeName>Kaitlin M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barlow</LastName><ForeName>Brooke</ForeName><Initials>B</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5118-7029</Identifier><AffiliationInfo><Affiliation>University of Kentucky Healthcare, Lexington, KY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeung</LastName><ForeName>Siu Yan Amy</ForeName><Initials>SYA</Initials><AffiliationInfo><Affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heavner</LastName><ForeName>Jason J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>University of Maryland Baltimore Washington Medical Center, Glen Burnie, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claassen</LastName><ForeName>Cassidy W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>University of Maryland School of Medicine, Center for International Health, Education, and Biosecurity, Institute of Human Virology, Lusaka, Zambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heavner</LastName><ForeName>Mojdeh S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>University of Maryland Medical Center, Department of Pharmacy, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacotherapy</MedlineTA><NlmUniqueID>8111305</NlmUniqueID><ISSNLinking>0277-0008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antivirals</Keyword><Keyword MajorTopicYN="N">Critical care</Keyword><Keyword MajorTopicYN="N">Cytochrome P450</Keyword><Keyword MajorTopicYN="N">Dialysis</Keyword><Keyword MajorTopicYN="N">Infectious disease</Keyword><Keyword MajorTopicYN="N">Liver</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics</Keyword><Keyword MajorTopicYN="N">Pharmacology</Keyword><Keyword MajorTopicYN="N">Renal</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32259313</ArticleId><ArticleId IdType="doi">10.1002/phar.2398</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Zambie</li><li>États-Unis</li></country><region><li>Kentucky</li><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Barlow, Ashley" sort="Barlow, Ashley" uniqKey="Barlow A" first="Ashley" last="Barlow">Ashley Barlow</name></region><name sortKey="Barlow, Brooke" sort="Barlow, Brooke" uniqKey="Barlow B" first="Brooke" last="Barlow">Brooke Barlow</name><name sortKey="Heavner, Jason J" sort="Heavner, Jason J" uniqKey="Heavner J" first="Jason J" last="Heavner">Jason J. Heavner</name><name sortKey="Heavner, Mojdeh S" sort="Heavner, Mojdeh S" uniqKey="Heavner M" first="Mojdeh S" last="Heavner">Mojdeh S. Heavner</name><name sortKey="Landolf, Kaitlin M" sort="Landolf, Kaitlin M" uniqKey="Landolf K" first="Kaitlin M" last="Landolf">Kaitlin M. Landolf</name><name sortKey="Yeung, Siu Yan Amy" sort="Yeung, Siu Yan Amy" uniqKey="Yeung S" first="Siu Yan Amy" last="Yeung">Siu Yan Amy Yeung</name></country><country name="Zambie"><noRegion><name sortKey="Claassen, Cassidy W" sort="Claassen, Cassidy W" uniqKey="Claassen C" first="Cassidy W" last="Claassen">Cassidy W. Claassen</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000251 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000251 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:32259313
|texte= Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32259313" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |